Accession PRJCA019485
Title Pembrolizumab Combined with Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma (Keystone-001)
Relevance Medical
Data types Transcriptome or Gene expression
Raw sequence reads
Organisms Homo sapiens
Description Neoadjuvant pembrolizumab pluschemotherapy, followed by Da Vinci robotic-assisted surgery, was effective and safe forresectable ESCC. The expansion of TRGC2+ NKT cells in peripheral blood maypredict treatment response.
Sample scope Single cell
Release date 2023-09-12
Grants
Agency program Grant ID Grant title
Beijing Xisike Clinical Oncology Research Foundation Y-MSD2020-0346
Beijing Xisike Clinical Oncology Research Foundation Y-MSDZD2021-0239
Beijing-Tianjin-Hebei Basic Research Project of Tianjin Science and Technology Bureau 20JCZXJC00050
Beijing-Tianjin-Hebei Basic Research Project of Tianjin Science and Technology Bureau 22JCZXJC00040
Public Health Science and Technology Major Project of the Tianjin Science and Technology Bureau 21ZXGWSY00020
Construction Project of Precision Treatment of Oncology Surgery in the Tianjin Medical University Cancer Hospital ZLWKJZZL02
The "14th Five-Year" Peak Discipline Support Program of the Tianjin Medical University Cancer Institute and Hospital 7-2-17
"358" Clinical Research Special Fund of the Tianjin Medical University Cancer Institute and Hospital NA
Tianjin Key Medical Discipline (Specialty) Construction Project TJYXZDXK-010A
Submitter Hongjing Jiang (18622923282@163.com)
Organization Tianjin Medical University Cancer Institute and Hospital
Submission date 2023-09-03

Project Data

Resource name Description